Sodium valproate (VPA) antibody and antigen (hapten, BSA/OVA conjugated)
Diagnostic anti-Sodium valproate (VPA) antibodies (anti-Sodium valproate, anti-VPA) and diagnostic hapten-carrier conjugates BSA-Sodium valproate (VPA), OVA-Sodium valproate (VPA), KLH-Sodium valproate (VPA) antigens for Epilepsy VPA detection in ELISA test, competitive ELISA, Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-SMT-VPA-Ag01 | BSA-Sodium valproate (VPA) | 756 |
GMP-SMT-VPA-Ag02 | OVA-Sodium valproate (VPA) | 756 |
GMP-SMT-VPA-Ab01 | Anti-human Sodium valproate (VPA) mouse monoclonal antibody (mAb) | 1953 |
GMP-SMT-VPA-Ab02 | Anti-human Sodium valproate (VPA) human monoclonal antibody (mAb) | 1953 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-SMT-VPA-Ag01 |
Product Name | BSA-Sodium valproate (VPA) |
Target/Biomarker | Sodium valproate (VPA) |
Expression platform | Synthetic |
Isotypes | NA |
Bioactivity validation | Sodium valproate (VPA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in VPA level test of Epilepsy (toxicity) and related syndrome evaluation. |
Tag | NA |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Sodium valproate (VPA) / OVA-Sodium valproate (VPA) is Synthetic. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-SMT-VPA-Ag02 |
Product Name | OVA-Sodium valproate (VPA) |
Target/Biomarker | Sodium valproate (VPA) |
Expression platform | Synthetic |
Isotypes | NA |
Bioactivity validation | Sodium valproate (VPA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in VPA level test of Epilepsy (toxicity) and related syndrome evaluation. |
Tag | NA |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Sodium valproate (VPA) / OVA-Sodium valproate (VPA) is Synthetic. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-SMT-VPA-Ab01 |
Product Name | Anti-human Sodium valproate (VPA) mouse monoclonal antibody (mAb) |
Target/Biomarker | Sodium valproate (VPA) |
Expression platform | Hybridoma |
Isotypes | Mouse IgG |
Bioactivity validation | Sodium valproate (VPA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in VPA level test of Epilepsy (toxicity) and related syndrome evaluation. |
Tag | mFc |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Sodium valproate (VPA) / OVA-Sodium valproate (VPA) is Synthetic. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-SMT-VPA-Ab02 |
Product Name | Anti-human Sodium valproate (VPA) human monoclonal antibody (mAb) |
Target/Biomarker | Sodium valproate (VPA) |
Expression platform | Hybridoma |
Isotypes | Mouse IgG |
Bioactivity validation | Sodium valproate (VPA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in VPA level test of Epilepsy (toxicity) and related syndrome evaluation. |
Tag | mFc |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Sodium valproate (VPA) / OVA-Sodium valproate (VPA) is Synthetic. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
Valproate (VPA) and its valproic acid, sodium valproate, and valproate semisodium forms are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches. They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.